Atrium Therapeutics, Inc. (RNA) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Hold
Based on 16 analysts92.2% Below Target
RNA trades 92.2% below Wall Street's consensus target of $25.00.
Current Price$13.01
Average Target$25.00
Low$25.00
Median$25.00
High$25.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth+79.7%
(High Growth)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes RNA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 16 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
RNA Price Target Analysis
Updated July 7, 2026As of July 7, 2026, Atrium Therapeutics, Inc. (RNA) has a Wall Street consensus price target of $25.00, based on estimates from 16 covering analysts. With the stock currently trading at $13.01, this represents a potential upside of +92.2%. The company has a market capitalization of $223M.
Analyst price targets range from a low of $25.00 to a high of $25.00, representing a 0% spread in expectations. The median target of $25.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 7 analysts rating the stock as a Buy or Strong Buy,9 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, RNA trades at a trailing P/E of -2.9x. Analysts expect EPS to grow +79.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+36.7%
Industry Consensus
Avg Forward P/E
25.0x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SRPTSarepta Therapeutics, Inc. | $2.0B | $19.18 | $25.14 | +31.1% | Buy | 5.4x | 54 |
 MDWDMediWound Ltd. | $159M | $14.64 | $27.00 | +84.4% | Buy | — | 13 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 RAREUltragenyx Pharmaceutical Inc. | $3.3B | $33.70 | $47.11 | +39.8% | Buy | — | 33 |
 BMRNBioMarin Pharmaceutical Inc. | $11.3B | $58.79 | $89.21 | +51.7% | Buy | 11.9x | 41 |
 ALNYAlnylam Pharmaceuticals, Inc. | $41.8B | $313.04 | $450.64 | +44.0% | Buy | 42.1x | 52 |
 IONSIonis Pharmaceuticals, Inc. | $13.7B | $83.18 | $106.50 | +28.0% | Buy | — | 32 |
 ARWRArrowhead Pharmaceuticals, Inc. | $12.2B | $86.55 | $91.00 | +5.1% | Buy | — | 21 |
 NTLAIntellia Therapeutics, Inc. | $2.0B | $17.84 | $26.13 | +46.5% | Buy | — | 39 |
 BEAMBeam Therapeutics Inc. | $3.6B | $35.32 | $48.00 | +35.9% | Buy | — | 27 |
RNA — Frequently Asked Questions
Quick answers to the most common questions about buying RNA stock.
What is the RNA stock price target for 2026?
The consensus Wall Street price target for RNA is $25, representing 92.2% upside from the current price of $13.01. With 16 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is RNA a buy, sell, or hold?
RNA has a consensus rating of "Hold" based on 16 Wall Street analysts. The rating breakdown is mixed, with 9 Hold ratings making up the largest segment. The consensus 12-month price target of $25 implies 92.2% upside from current levels.
Is RNA stock overvalued or undervalued?
RNA's current price is $13.01 with a consensus target of $25 (92.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can RNA stock go?
The most bullish Wall Street analyst has a price target of $25 for RNA, while the most conservative target is $25. The consensus of $25 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover RNA stock?
RNA is well covered by analysts, with 16 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 9 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the RNA stock forecast?
The 12-month RNA stock forecast based on 16 Wall Street analysts shows a consensus price target of $25, with estimates ranging from $25 (bear case) to $25 (bull case). The median consensus rating is "Hold".
Should I buy RNA stock?
Wall Street analysts are very optimistic on RNA, with a "Hold" consensus rating and $25 price target (92.2% upside). 7 of 16 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do RNA price targets vary so much?
RNA analyst price targets range from $25 to $25, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $25 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare